Reuters: Health News 5 April 2018

AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023

(Reuters) - AbbVie Inc on Thursday said it signed a deal with Biogen Inc and its joint venture partner Samsung Bioepis that would fend off U.S. competition of their rival version to blockbuster drug Humira until 2023.

Read More →

Bulgaria reports H5N8 bird flu outbreak in duck farm

SOFIA (Reuters) - Bulgaria's authorities reported an outbreak of the highly pathogenic H5N8 bird flu virus on a duck farm in the southeastern region of Yambol, the food safety agency said on Thursday.

Read More →

Novo Nordisk buys blood drug licence to boost anaemic biopharma business

COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk has secured the global licence for U.S. biotech company EpiDestiny's sickle cell disease (SCD) program in a bid to offset declining sales in its biopharmaceutical business.

Read More →

Hopes rise for Shire sale as Takeda CEO discusses case for deal

LONDON (Reuters) - Expectations that Takeda Pharmaceutical will bid for London-listed rare disease specialist Shire before an April 25 deadline rose on Thursday after comments from the head of the Japanese drugmaker on the merits of a deal.

Read More →